European Journal of Cancer

Papers
(The H4-Index of European Journal of Cancer is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies246
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients231
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers227
The cost of cancer in Europe 2018169
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment164
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment139
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts135
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)123
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention120
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CAC118
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms116
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial116
Global, regional and national burden of primary liver cancer by subtype116
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts109
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective108
Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review107
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis106
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis100
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation100
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations98
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–201698
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR98
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 202296
Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review95
Evidence-based recommendations on categories for extent of resection in diffuse glioma94
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation93
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status88
Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer87
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 202286
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials85
A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-1985
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and84
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study84
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology83
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 201981
Evolution of low HER2 expression between early and advanced-stage breast cancer81
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy79
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoi79
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing77
Selenium stimulates the antitumour immunity: Insights to future research77
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel pr76
Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey73
SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death71
Exosomes and exosomal RNAs in breast cancer: A status update71
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial70
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials70
Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review70
Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)70
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment69
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy66
Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review66
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study63
Applications of single-cell and bulk RNA sequencing in onco-immunology62
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients61
The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients61
Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds60
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study59
Systemic treatment of brain metastases in non-small cell lung cancer59
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy58
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency58
0.03541088104248